TTY Biopharm Co Ltd (TWO:4105) — Market Cap & Net Worth
Market Cap & Net Worth: TTY Biopharm Co Ltd (4105)
TTY Biopharm Co Ltd (TWO:4105) has a market capitalization of $575.79 Million (NT$18.28 Billion) as of June 20, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #11650 globally and #441 in its home market, demonstrating a -1.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TTY Biopharm Co Ltd's stock price NT$73.50 by its total outstanding shares 248649959 (248.65 Million). Review 4105 total liabilities to assess the company's total debt and financial obligations.
TTY Biopharm Co Ltd Market Cap History: 2015 to 2026
TTY Biopharm Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $642.40 Million to $575.79 Million (1.33% CAGR).
TTY Biopharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TTY Biopharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
TTY Biopharm Co Ltd's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.41x
TTY Biopharm Co Ltd's market cap is 0.41 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $601.01 Million | $4.08 Billion | $1.34 Billion | 0.15x | 0.45x |
| 2018 | $470.91 Million | $4.04 Billion | $1.46 Billion | 0.12x | 0.32x |
| 2019 | $534.57 Million | $4.47 Billion | $900.08 Million | 0.12x | 0.59x |
| 2020 | $468.37 Million | $4.22 Billion | $924.18 Million | 0.11x | 0.51x |
| 2021 | $494.62 Million | $4.54 Billion | $831.89 Million | 0.11x | 0.59x |
| 2022 | $625.47 Million | $5.06 Billion | $1.09 Billion | 0.12x | 0.57x |
| 2023 | $629.84 Million | $5.51 Billion | $1.13 Billion | 0.11x | 0.56x |
| 2024 | $570.30 Million | $5.89 Billion | $1.45 Billion | 0.10x | 0.39x |
| 2025 | $638.46 Million | $6.45 Billion | $1.56 Billion | 0.10x | 0.41x |
Competitor Companies of 4105 by Market Capitalization
Companies near TTY Biopharm Co Ltd in the global market cap rankings as of June 20, 2026.
Key companies related to TTY Biopharm Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #554 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #602 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #554 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #602 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.50 |
TTY Biopharm Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, TTY Biopharm Co Ltd's market cap moved from $642.40 Million to $ 575.79 Million, with a yearly change of 1.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$575.79 Million | -9.82% |
| 2025 | NT$638.46 Million | +11.95% |
| 2024 | NT$570.30 Million | -9.45% |
| 2023 | NT$629.84 Million | +0.70% |
| 2022 | NT$625.47 Million | +26.45% |
| 2021 | NT$494.62 Million | +5.60% |
| 2020 | NT$468.37 Million | -12.38% |
| 2019 | NT$534.57 Million | +13.52% |
| 2018 | NT$470.91 Million | -21.65% |
| 2017 | NT$601.01 Million | +3.97% |
| 2016 | NT$578.06 Million | -10.02% |
| 2015 | NT$642.40 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 20th, 2026 the market cap of TTY Biopharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $575.79 Million USD |
| MoneyControl | $575.79 Million USD |
| MarketWatch | $575.79 Million USD |
| marketcap.company | $575.79 Million USD |
| Reuters | $575.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TTY Biopharm Co Ltd
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers … Read more